{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:23:57Z","timestamp":1791685437369,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82771-3","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:15:57Z","timestamp":1735373757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New class of thio\/semicarbazide-based benzyloxy derivatives as selective class of monoamine oxidase-B inhibitors"],"prefix":"10.1038","volume":"14","author":[{"given":"Namitha","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiseong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabitha","family":"Prabhakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachithra Thazhathuveedu","family":"Sudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della Grace Thomas","family":"Parambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq G.","family":"Alsahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"82771_CR1","doi-asserted-by":"crossref","unstructured":"Parambi, D. G. T. et al. Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases. In Molecular Neurobiologyvol. 59 (Springer US, 2022).","DOI":"10.1007\/s12035-021-02555-y"},{"key":"82771_CR2","doi-asserted-by":"publisher","first-page":"104203","DOI":"10.1016\/j.bioorg.2020.104203","volume":"104","author":"F Rodr\u00edguez-Enr\u00edquez","year":"2020","unstructured":"Rodr\u00edguez-Enr\u00edquez, F. et al. Novel coumarin-pyridazine hybrids as selective MAO-B inhibitors for the Parkinson\u2019s disease therapy. Bioorg. Chem. 104, 104203 (2020).","journal-title":"Bioorg. Chem."},{"key":"82771_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bioorg.2017.10.001","volume":"75","author":"SMA Abid","year":"2017","unstructured":"Abid, S. M. A. et al. Sulfonyl hydrazones derived from 3-formylchromone as non-selective inhibitors of MAO-A and MAO-B: synthesis, molecular modelling and in-silico ADME evaluation. Bioorg. Chem. 75, 291\u2013302 (2017).","journal-title":"Bioorg. Chem."},{"key":"82771_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/0091270005277935","volume":"45","author":"JJ Chen","year":"2005","unstructured":"Chen, J. J. & Swope, D. M. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. 45, 878\u2013894 (2005).","journal-title":"J. Clin. Pharmacol."},{"key":"82771_CR5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost, W. H. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J. Neural Transm. 129, 723\u2013736 (2022).","journal-title":"J. Neural Transm."},{"key":"82771_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jocn.2021.05.056","volume":"90","author":"J Pagonabarraga","year":"2021","unstructured":"Pagonabarraga, J., Tinazzi, M., Caccia, C. & Jost, W. H. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson\u2019s disease: clinical cases and a review of the literature. J. Clin. Neurosci. 90, 178\u2013183 (2021).","journal-title":"J. Clin. Neurosci."},{"key":"82771_CR7","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1021\/acsomega.2c07694","volume":"8","author":"S Kumar","year":"2023","unstructured":"Kumar, S. et al. Development of Isopropyl-Tailed Chalcones as a new class of selective MAO-B inhibitors for the treatment of Parkinson\u2019s disorder. ACS Omega. 8, 6908\u20136917 (2023).","journal-title":"ACS Omega"},{"key":"82771_CR8","doi-asserted-by":"crossref","unstructured":"Ipe, R. S. et al. A Concise Review of the Recent Structural Explorations of Chromones as MAO-B Inhibitors: Update from 2017 to 2023 (2023).","DOI":"10.3390\/ph16091310"},{"key":"82771_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/cbdd.13919","volume":"98","author":"VP Koyiparambath","year":"2021","unstructured":"Koyiparambath, V. P. et al. Deciphering the detailed structure\u2013activity relationship of coumarins as Monoamine oxidase enzyme inhibitors\u2014An updated review. Chem. Biol. Drug Des. 98, 655\u2013673 (2021).","journal-title":"Chem. Biol. Drug Des."},{"key":"82771_CR10","doi-asserted-by":"publisher","first-page":"37731","DOI":"10.1021\/acsomega.3c05883","volume":"8","author":"J Jayan","year":"2023","unstructured":"Jayan, J. et al. Piperidine: a versatile heterocyclic ring for developing monoamine oxidase inhibitors. ACS Omega 8, 37731\u201337751 (2023).","journal-title":"ACS Omega"},{"key":"82771_CR11","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.2174\/1568026621999210902123132","volume":"21","author":"TM Rangarajan","year":"2021","unstructured":"Rangarajan, T. M. & Mathew, B. Recent updates on Pyrazoline Derivatives as promising candidates for neuropsychiatric and neurodegenerative disorders. Curr. Top. Med. Chem. 21, 2695\u20132714 (2021).","journal-title":"Curr. Top. Med. Chem."},{"key":"82771_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1021\/jm970599m","volume":"41","author":"P Pevarello","year":"1998","unstructured":"Pevarello, P. et al. Synthesis and anticonvulsant activity of a new class of 2- [(arylalkyl)amino]alkanamide derivatives. J. Med. Chem. 41, 579\u2013590 (1998).","journal-title":"J. Med. Chem."},{"key":"82771_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/bdd.540","volume":"28","author":"AM Ahmad","year":"2007","unstructured":"Ahmad, A. M. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm. Drug Dispos. 28, 135\u2013143 (2007).","journal-title":"Biopharm. Drug Dispos."},{"key":"82771_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainresbull.2020.12.018","volume":"168","author":"H Wasan","year":"2021","unstructured":"Wasan, H., Singh, D. & KH, R. Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res. Bull. 168, 165\u2013177 (2021).","journal-title":"Brain Res. Bull."},{"key":"82771_CR15","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.2147\/DDDT.S302673","volume":"15","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese, G., Barone, P., Lopiano, L. & Stocchi, F. The current evidence for the use of safinamide for the treatment of parkinson\u2019s disease. Drug Des. Dev. Ther. 15, 2507\u20132517 (2021).","journal-title":"Drug Des. Dev. Ther."},{"key":"82771_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42452-020-03661-7","volume":"2","author":"AE Ledesma","year":"2020","unstructured":"Ledesma, A. E., Catal\u00e1n, C. A. N. & Brand\u00e1n, S. A. A combined theoretical and experimental study on the structure, vibrational, and electronic properties of antiparkinsonian drug safinamide. SN Appl. Sci. 2, 1\u201316 (2020).","journal-title":"SN Appl. Sci."},{"key":"82771_CR17","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1021\/jm070677y","volume":"50","author":"C Binda","year":"2007","unstructured":"Binda, C. et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. J. Med. Chem. 50, 5848\u20135852 (2007).","journal-title":"J. Med. Chem."},{"key":"82771_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cdc.2018.10.009","volume":"17\u201318","author":"M Joy","year":"2018","unstructured":"Joy, M., Mathew, B. & Sudarsanakumar, C. Structural features of Safinamide: a combined Hirshfeld surface analysis & quantum chemical treatment. Chem. Data Collect. 17\u201318, 404\u2013414 (2018).","journal-title":"Chem. Data Collect."},{"key":"82771_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2022.1002547","volume":"10","author":"L Pisani","year":"2022","unstructured":"Pisani, L. et al. A twenty-year journey exploring coumarin-based derivatives as bioactive molecules. Front. Chem. 10, 1\u20138 (2022).","journal-title":"Front. Chem."},{"key":"82771_CR20","doi-asserted-by":"publisher","first-page":"2200084","DOI":"10.1002\/ardp.202200084","volume":"355","author":"ST Sudevan","year":"2022","unstructured":"Sudevan, S. T. et al. Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidase-B inhibitors. Arch. Pharm. (Weinheim) 355, 2200084 (2022).","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"82771_CR21","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1021\/jm060183l","volume":"49","author":"M Catto","year":"2006","unstructured":"Catto, M. et al. Structural insights into monoamine oxidase inhibitory potency and selectivity of 7-substituted coumarins from ligand- and target-based approaches. J. Med. Chem. 49, 4912\u20134925 (2006).","journal-title":"J. Med. Chem."},{"key":"82771_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11696-020-01332-w","volume":"75","author":"YJ Rao","year":"2021","unstructured":"Rao, Y. J., Abhijit, K., Mallikarjun, G. & Hemasri, Y. Design and synthesis of novel benzyloxy-tethered-chromone-carboxamide derivatives as potent and selective human monoamine oxidase-b inhibitors. Chem. Pap. 75, 703\u2013716 (2021).","journal-title":"Chem. Pap."},{"key":"82771_CR23","doi-asserted-by":"publisher","first-page":"105581","DOI":"10.1016\/j.bioorg.2021.105581","volume":"119","author":"D Knez","year":"2022","unstructured":"Knez, D. et al. Indoles and 1-(3-(benzyloxy)benzyl)piperazines: reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library. Bioorg. Chem. 119, 105581 (2022).","journal-title":"Bioorg. Chem."},{"key":"82771_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/cbdd.14238","volume":"102","author":"AK Singh","year":"2023","unstructured":"Singh, A. K. et al. Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones. Chem. Biol. Drug Des. 102, 271\u2013284 (2023).","journal-title":"Chem. Biol. Drug Des."},{"key":"82771_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bioorg.2018.03.029","volume":"79","author":"SU Qazi","year":"2018","unstructured":"Qazi, S. U. et al. Semicarbazone derivatives as urease inhibitors: synthesis, biological evaluation, molecular docking studies and in-silico ADME evaluation. Bioorg. Chem. 79, 19\u201326 (2018).","journal-title":"Bioorg. Chem."},{"key":"82771_CR26","doi-asserted-by":"publisher","first-page":"105209","DOI":"10.1016\/j.bioorg.2021.105209","volume":"115","author":"SU Qazi","year":"2021","unstructured":"Qazi, S. U. et al. Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors: synthesis, characterization, biological evaluation, molecular docking, and kinetic studies. Bioorg. Chem. 115, 105209 (2021).","journal-title":"Bioorg. Chem."},{"key":"82771_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1080\/13102818.2022.2098819","volume":"36","author":"J Mitkov","year":"2022","unstructured":"Mitkov, J., Kondeva-Burdina, M., Peikova, L., Georgieva, M. & Zlatkov, A. Design, synthesis and evaluation of semi- and thiosemicarbazides containing a methylxanthine moiety with in vitro neuroprotective and MAO-B inhibitory activities. Biotechnol. Biotechnol. Equip. 36, 486\u2013499 (2022).","journal-title":"Biotechnol. Biotechnol. Equip."},{"key":"82771_CR28","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1080\/07391102.2020.1782266","volume":"39","author":"GE Mathew","year":"2021","unstructured":"Mathew, G. E. et al. Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease. J. Biomol. Struct. Dyn. 39, 4786\u20134794 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"82771_CR29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.procbio.2020.05.016","volume":"99","author":"GE Mathew","year":"2020","unstructured":"Mathew, G. E. et al. Inhibitions of monoamine oxidases and acetylcholinesterase by 1-methyl, 5-phenyl substituted thiosemicarbazones: synthesis, biochemical, and computational investigations. Process. Biochem. 99, 246\u2013253 (2020).","journal-title":"Process. Biochem."},{"key":"82771_CR30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1039\/C8MD00399H","volume":"9","author":"B Mathew","year":"2018","unstructured":"Mathew, B. et al. Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. Medchemcomm 9, 1871\u20131881 (2018).","journal-title":"Medchemcomm"},{"key":"82771_CR31","doi-asserted-by":"crossref","unstructured":"Oh, J. M. et al. Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors. Molecules 25 (2020).","DOI":"10.3390\/molecules25102356"},{"key":"82771_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-0716-3662-6_24","volume":"2761","author":"B Mathew","year":"2024","unstructured":"Mathew, B. et al. Enzyme inhibition assays for monoamine oxidase. Methods Mol. Biol. 2761, 329\u2013336 (2024).","journal-title":"Methods Mol. Biol."},{"key":"82771_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bioorg.2018.10.051","volume":"83","author":"SC Baek","year":"2019","unstructured":"Baek, S. C. et al. Rhamnocitrin isolated from Prunus padus var. Seoulensis: a potent and selective reversible inhibitor of human monoamine oxidase A. Bioorg. Chem. 83, 317\u2013325 (2019).","journal-title":"Bioorg. Chem."},{"key":"82771_CR34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bmcl.2018.01.049","volume":"28","author":"SC Baek","year":"2018","unstructured":"Baek, S. C. et al. Selective inhibition of monoamine oxidase A by hispidol. Bioorg. Med. Chem. Lett. 28, 584\u2013588 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"82771_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijbiomac.2020.02.144","volume":"151","author":"JM Oh","year":"2020","unstructured":"Oh, J. M. et al. Calycosin and 8-O-methylretusin isolated from Maackia amurensis as potent and selective reversible inhibitors of human monoamine oxidase-B. Int. J. Biol. Macromol. 151, 441\u2013448 (2020).","journal-title":"Int. J. Biol. Macromol."},{"key":"82771_CR36","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1016\/j.bmcl.2016.08.044","volume":"26","author":"HW Lee","year":"2016","unstructured":"Lee, H. W. et al. Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens. Bioorg. Med. Chem. Lett. 26, 4714\u20134719 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"82771_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","volume":"38","author":"L Di","year":"2003","unstructured":"Di, L., Kerns, E. H., Fan, K., McConnell, O. J. & Carter, G. T. High throughput artificial membrane permeability assay for blood\u2013brain barrier. Eur. J. Med. Chem. 38, 223\u2013232 (2003).","journal-title":"Eur. J. Med. Chem."},{"key":"82771_CR38","first-page":"265","volume":"6","author":"N Ameen","year":"2016","unstructured":"Ameen, N. & Shafi, S. Biochemical and In-Vivo antioxidant parameters for evaluation of memory enchancing activity. Int. J. Pharm. Chem. Biol. Sci. 6, 265\u2013270 (2016).","journal-title":"Int. J. Pharm. Chem. Biol. Sci."},{"key":"82771_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/09727531211051976","volume":"28","author":"PC Tiwari","year":"2021","unstructured":"Tiwari, P. C. et al. Biochemical and immunological studies on Protective Effect of Mangiferin in 6-Hydroxydopamine (6-OHDA)-Induced Parkinson\u2019s disease in rats. Ann. Neurosci. 28, 137\u2013149 (2021).","journal-title":"Ann. Neurosci."},{"key":"82771_CR40","doi-asserted-by":"crossref","unstructured":"Alqurashi, M. M. et al. Protective effect of sterubin against neurochemical and behavioral impairments in rotenone-induced Parkinson\u2019s disease. Braz. J. Med. Biol. Res 57 (2024).","DOI":"10.1590\/1414-431x2023e12829"},{"key":"82771_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-50600-8","volume":"14","author":"S Kumar","year":"2024","unstructured":"Kumar, S. et al. Machine learning driven web-based app platform for the discovery of monoamine oxidase B inhibitors. Sci. Rep. 14, 1\u201320 (2024).","journal-title":"Sci. Rep."},{"key":"82771_CR42","doi-asserted-by":"crossref","unstructured":"Son, S. Y. et al. Structure of human monoamine oxidase A at 2.2-\u00c5 resolution: The control of opening the entry for substrates\/inhibitors. Proc. Natl. Acad. Sci. U. S. A. 105, 5739\u20135744 (2008).","DOI":"10.1073\/pnas.0710626105"},{"key":"82771_CR43","unstructured":"Schr\u00f6dinger Release 2024-2: BioLuminate, Schr\u00f6dinger (LLC, 2024)."},{"key":"82771_CR44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/1062936X.2022.2041724","volume":"33","author":"R Girase","year":"2022","unstructured":"Girase, R., Ahmad, I., Pawara, R. & Patel, H. Optimizing cardio, hepato and phospholipidosis toxicity of the Bedaquiline by chemoinformatics and molecular modelling approach. SAR QSAR Environ. Res. 33, 215\u2013235 (2022).","journal-title":"SAR QSAR Environ. Res."},{"key":"82771_CR45","unstructured":"Schr\u00f6dinger Release 2024-2: Desmond Molecular Dynamics System, Shaw, D. E. & Research New York, NY, Maestro-Desmond Interoperability Tools, Schr\u00f6dinger, New York, NY (2024)."},{"key":"82771_CR46","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1021\/acs.jpcb.6b09451","volume":"121","author":"B Mathew","year":"2017","unstructured":"Mathew, B. et al. Pharmacophore-based 3D-QSAR Analysis of thienyl chalcones as a new class of human MAO-B inhibitors: investigation of combined quantum chemical and molecular dynamics approach. J. Phys. Chem. B 121, 1186\u20131203 (2017).","journal-title":"J. Phys. Chem. B"},{"issue":"14","key":"82771_CR47","first-page":"1","volume":"141","author":"S Kumar","year":"2024","unstructured":"Kumar, S. et al. Isatin-tethered halogen-containing acylhydrazone derivatives as monoamine oxidase inhibitor with neuroprotective effect. Sci. Rep. 141 (14), 1\u201320 (2024).","journal-title":"Sci. Rep."},{"key":"82771_CR48","doi-asserted-by":"publisher","first-page":"47606","DOI":"10.1021\/acsomega.3c05719","volume":"8","author":"J Jayan","year":"2023","unstructured":"Jayan, J. et al. Development of a new class of monoamine oxidase-B inhibitors by fine-tuning the halogens on the acylhydrazones. ACS Omega 8, 47606\u201347615 (2023).","journal-title":"ACS Omega"},{"key":"82771_CR49","doi-asserted-by":"crossref","unstructured":"Thomas Parambi, D. G. et al. Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: synthesis, biochemistry, and molecular dynamics study. Comput. Biol. Chem. 105 (2023).","DOI":"10.1016\/j.compbiolchem.2023.107899"},{"key":"82771_CR50","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2174\/1871527318666190610111246","volume":"18","author":"B Mathew","year":"2019","unstructured":"Mathew, B. et al. Perspective design of chalcones for the management of CNS disorders: a mini-review. CNS Neurol. Disord. Drug Targets 18, 432\u2013445 (2019).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"82771_CR51","doi-asserted-by":"publisher","first-page":"136634","DOI":"10.1016\/j.molstruc.2023.136634","volume":"1295","author":"PR Krishnendu","year":"2024","unstructured":"Krishnendu, P. R. et al. A structure-based approach to explore novel COX-2 inhibitors using pharmacophore modelling, 3D-QSAR analysis, virtual screening and dynamics simulation study. J. Mol. Struct. 1295, 136634 (2024).","journal-title":"J. Mol. Struct."},{"key":"82771_CR52","doi-asserted-by":"crossref","unstructured":"Zrieq, R. et al. Tomatidine and patchouli alcohol as inhibitors of SARS-CoV-2 enzymes (3CLpro, PLpro and NSP15) by molecular docking and molecular dynamics simulations. Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms221910693"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82771-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82771-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T21:27:25Z","timestamp":1735421245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82771-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82771"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82771-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"22 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31292"}}